Buscar
Relay Therapeutics Inc
RLAYAñadir a la lista de seguimiento
18.650USD
+0.890+5.01%
Cierre 07/02, 13:00（ET）Cotizaciones retrasadas 15 min
3.24BCap. mercado
PérdidaP/E TTM
Más Datos de Relay Therapeutics Inc Compañía
Relay Therapeutics Inc. is a clinical-stage precision medicine company. The Company’s initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. Its Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company’s lead product candidates, such as RLY-2608. It is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including RLY-2608. RLY-2608 is an allosteric, pan-mutant and isoform-selective phosphoinostide 3 kinase alphas (PI3Kα), inhibitor in clinical development. It is the lead program in its efforts to discover and develop mutant selective inhibitors of PI3Kα.
Información de Relay Therapeutics Inc
Símbolo de cotizaciónRLAY
Nombre de la empresaRelay Therapeutics Inc
Fecha de salida a bolsaJul 16, 2020
Director ejecutivoPatel (Sanjiv K)
Número de empleados261
Tipo de seguridadOrdinary Share
Fin del año fiscalJul 16
Dirección60 Hampshire Street
CiudadCAMBRIDGE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal02139
Teléfono16173708837
Sitio Webhttps://relaytx.com/
Símbolo de cotizaciónRLAY
Fecha de salida a bolsaJul 16, 2020
Director ejecutivoPatel (Sanjiv K)
Ejecutivos de Relay Therapeutics Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Mark Murcko, Ph.D.
Dr. Mark Murcko, Ph.D.
Independent Director
Independent Director
996.95K
--
Mr. Peter (Pete) Rahmer
Mr. Peter (Pete) Rahmer
Chief Corporate Development Officer
Chief Corporate Development Officer
266.70K
-0.28%
Mr. Brian R. Adams, J.D.
Mr. Brian R. Adams, J.D.
Chief Legal Officer, Secretary
Chief Legal Officer, Secretary
229.91K
+22.16%
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Independent Director
Independent Director
25.00K
--
Dr. Sanjiv K. Patel, M.D.
Dr. Sanjiv K. Patel, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Donald A. Bergstrom, M.D., Ph.D.
Dr. Donald A. Bergstrom, M.D., Ph.D.
President - Research and Development
President - Research and Development
--
--
Mr. Thomas (Tom) Catinazzo
Mr. Thomas (Tom) Catinazzo
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Alexis A. Borisy
Mr. Alexis A. Borisy
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Linda A. Hill, Ph.D.
Dr. Linda A. Hill, Ph.D.
Independent Director
Independent Director
--
--
Dr. Sekar (Sek) Kathiresan, M.D.
Dr. Sekar (Sek) Kathiresan, M.D.
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Mark Murcko, Ph.D.
Dr. Mark Murcko, Ph.D.
Independent Director
Independent Director
996.95K
--
Mr. Peter (Pete) Rahmer
Mr. Peter (Pete) Rahmer
Chief Corporate Development Officer
Chief Corporate Development Officer
266.70K
-0.28%
Mr. Brian R. Adams, J.D.
Mr. Brian R. Adams, J.D.
Chief Legal Officer, Secretary
Chief Legal Officer, Secretary
229.91K
+22.16%
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Independent Director
Independent Director
25.00K
--
Dr. Sanjiv K. Patel, M.D.
Dr. Sanjiv K. Patel, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Donald A. Bergstrom, M.D., Ph.D.
Dr. Donald A. Bergstrom, M.D., Ph.D.
President - Research and Development
President - Research and Development
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Relay Therapeutics Inc?
Los cinco principales accionistas de Relay Therapeutics Inc son: Dr. Mark Murcko, Ph.D.
¿Cuántas instituciones poseen acciones de Relay Therapeutics Inc (RLAY)?
A fecha de 2026Q1, 474 instituciones poseen acciones de Relay Therapeutics Inc, con un valor de mercado combinado de aproximadamente 194.30M, lo que representa el 101.48% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -3648091.00.